MedTrace Logo

TACE With Drug Eluting Beads Loaded With Doxorubicin in Liver Metastases From Melanoma Patients

NCT01409733 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-08-04

No results posted yet for this study

Summary

The Aim is to evaluate safety and efficacy of TACE with doxorubicin-loaded DC beads in melanoma patients with liver metastasis. This is a pilot study with the aim of recruiting 20 patients, this is a feasibility study. the patients profile is patients with stage IV Melanoma with liver metastases.

Conditions

  • Stage IV Melanoma Patients With Unresectable Liver Metastases

Interventions

DEVICE

TACE using Drug Eluting Beads loaded with Doxorubicin

100-300 microns DC Beads loaded with Doxorubicin (75mg of Doxorubixcin per vial)

Sponsors & Collaborators

  • University Hospital Tuebingen

    collaborator OTHER

  • SLK Kliniken Heilbronn GmbH

    collaborator OTHER

  • Heidelberg University

    lead OTHER

Principal Investigators

  • Philippe Pereira, MD · SLK Klninikum

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2012-09-30
Completion
2012-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01409733 on ClinicalTrials.gov